Research led by the Tulane National Primate Research Center (TNPRC) has identified and replicated a hyperimmune response in nonhuman primates that could one day lead to treatments for people with severe cases of COVID-19.
“This may be an important first step in understanding why some people become critically ill from COVID-19,” said senior author Jay Rappaport, director of the center. “Once we understand that, we will be better equipped to treat them.”
Most of the more than 2 million deaths caused by severe COVID-19 are the result of a hyperimmune response in the body that can rapidly cascade into respiratory failure.
Veterinary pathologist and corresponding author Robert Blair says that this is the first time scientists have observed acute respiratory distress syndrome (ARDS) in a nonhuman primate model of COVID-19.
“Although severe disease is only seen in a small subset of those infected with SARS-CoV-2, it is this outcome and our minimal understanding of it that has resulted in global unrest and the deaths of nearly 2 million people worldwide,” Blair said.
HYPERIMMUNE RESPONSE AND SEVERE DISEASE
Treatments for severe COVID-19 must be evaluated for safety and effectiveness in animals before being used in the human population and that can only occur if an animal can faithfully reproduce, or model, the full spectrum of disease as humans experience it.
The early results of the new study, published in the American Journal of Pathology, indicate that the African green monkey may be a highly useful model to test therapeutic strategies that can prevent or lessen severe disease in SARS-CoV-2 infected patients.
Researchers at TNPRC observed severe disease in aged African green monkeys exposed to SARS-CoV-2 that mimics what doctors see in their most critically ill patients. Two research subjects exhibited ARDS, a common and often fatal presentation in humans characterized by rapid onset respiratory failure, widespread inflammation, and fluid accumulation in the lungs.
ARDS is the hallmark sign of severe SARS-CoV-2 infection, a condition which makes it difficult for patients to breathe and hard for doctors to treat.
Subjects also developed a severe inflammatory response known as cytokine release syndrome, or “cytokine storm.” Cytokine storm occurs when a large number of cell-signaling proteins are released together, including the cytokine IL-6.
Critically ill COVID-19 patients who develop ARDS experience elevated IL-6 levels. Together, ARDS and cytokine storm are indicative of a runaway immune system in a subject whose inflammatory response is causing more harm than good.
Researchers have evaluated a variety of animal species in an attempt to understand what happens in the human body when infection with coronavirus does not present as a mild infection, as it does in 80% of cases, but instead produces the kind of severe disease that leads to hospitalization and death. But most animals, like humans, only present with mild to moderate disease.
Read the study: https://ajp.amjpathol.org/article/S0002-9440(20)30497-1/fulltext#secsectitle0075